Its not quarter on quarter growth, its PCP growth. If we get 33% PCP growth each quarter than our annual growth will be 33% which is poor for a 'breakthrough' product.
Perhaps new hospitals are getting there first order free or something?
And what is the story with Europe? I get that ahz is operating poorly there but surely the products are being requested by surgeons by now?
Ann: Appendix 4C - quarterly, page-12
-
- There are more pages in this discussion • 175 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |